Euclidean Technologies Management, LLC Regeneron Pharmaceuticals, Inc. Transaction History
Euclidean Technologies Management, LLC
- $109 Million
- Q1 2023
A detailed history of Euclidean Technologies Management, LLC transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, Euclidean Technologies Management, LLC holds 263 shares of REGN stock, worth $220,446. This represents 0.2% of its overall portfolio holdings.
Number of Shares
263Holding current value
$220,446% of portfolio
0.2%Shares
1 transactions
Others Institutions Holding REGN
# of Institutions
1,480Shares Held
85.5MCall Options Held
908KPut Options Held
1.3M-
Vanguard Group Inc Valley Forge, PA8.99MShares$7.54 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY8.45MShares$7.08 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY8.28MShares$6.94 Billion0.77% of portfolio
-
State Street Corp Boston, MA4.84MShares$4.06 Billion0.23% of portfolio
-
Capital World Investors Los Angeles, CA4.64MShares$3.89 Billion0.82% of portfolio
About REGENERON PHARMACEUTICALS, INC.
- Ticker REGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 107,190,000
- Market Cap $89.8B
- Description
- Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...